Summit Therapeutics (SMMT) PT Raised to $30 at Needham & Company Amid Sarepta Deal

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. SPY
7. CVS
8. UNH
9. TMUS
10. LMT

Go back to Summit Therapeutics (SMMT) PT Raised to $30 at Needham & Company Amid Sarepta Deal

Summit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement With Sarepta Therapeutics for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duc

October 4, 2016 7:01 AM EDT

OXFORD, United Kingdom, Oct. 04, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ: SMMT) (AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (DMD) and Clostridium difficile infection, announces that in conjunction with todays announcement on an exclusive license and collaboration agreement with Sarepta Therapeutics for European rights to... More